#quercetin

1 article

A wide, softly lit editorial still life on a pale warm-gray stone surface, shot from a slightly elevated three-quarter angle. On the left, a small cluster of fresh yellow-gold onions with papery skins, one cut in half to show its pale concentric layers, sits beside a few dusty-red capers and a sprig of dill. These are natural quercetin sources and read as quiet botanical details. In the center, a minimalist glass apothecary dish holds a few small, round, off-white tablets. Beside it, a slim amber glass vial lies on its side with a plain unlabeled cap.

On the right, a neatly arranged clinical element: a vintage-style wooden-handled stopwatch and a crisp paper stride-length measuring tape curled in a loose spiral, hinting at the 6-minute walk test and gait speed measures. Behind these, a softly out-of-focus wall of pale sage green with a subtle shadow of a window frame cast diagonally across it. A single translucent anatomical line drawing of lungs, rendered in fine charcoal ink on cream paper, leans against the wall, its delicate branching bronchi echoing the veining of a nearby green leaf.

Lighting is soft morning daylight from the upper left, creating gentle long shadows and a calm, thoughtful mood. The palette is muted and modern: butter yellow, sage, cream, warm gray, with small accents of terracotta and amber. Shallow depth of field keeps the tablets and onion sharp while the background melts into a creamy blur. Generous negative space across the upper right makes room for headline overlay. The composition feels like a contemporary science journal or wellness-research magazine cover: clean, tactile, restrained, with subtle film grain and natural color grading. No text, no logos, no people, no futuristic elements.

Primii oameni care au luat dasatinib + quercetin: ce a arătat (și ce nu a arătat) studiul pilot pe 14 pacienţi cu IPF

BY DR. SYNAPSE · 15 oct. 2026

În 2019, cercetătorii au raportat prima utilizare umană a combinaţiei senolitice dasatinib + quercetin, pe 14 pacienţi cu fibroza pulmonară idiopatică. După trei săptămâni de administrare intermitentă, participanţii au înregistrat creşteri semnificative ale distanţei parcurse în 6 minute, vitezei de mers şi timpului de ridicare de pe scaun, deşi funcţia pulmonară nu s‑a modificat. Studiul a consemnat un eveniment advers grav şi numeroase reclamaţii respiratorii, cutanate şi gastrointestinale. Totuşi, era un studiu deschis, necontrolat, al unui medicament anticancer cu un flavonoid la doză farmaceutică, nu un protocol de suplimente. Iată ce a testat efectiv trialul, ce a constatat şi cum să‑l citim critic.

#quercetin

Primii oameni care au luat dasatinib + quercetin: ce a arătat (și ce nu a arătat) studiul pilot pe 14 pacienţi cu IPF

Primii oameni care au luat dasatinib + quercetin: ce a arătat (și ce nu a arătat) studiul pilot pe 14 pacienţi cu IPF